LOCUS CELL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 31.9 TWD | -0.31% |
|
-1.54% | +1.27% |
| Sales 2022 | 0.6 19.37 0.82 | Sales 2023 | 0.41 13.1 0.56 | Capitalization | 6.3B 203B 8.62B |
|---|---|---|---|---|---|
| Net income 2022 | -53M -1.71B -72.53M | Net income 2023 | -96M -3.1B -131M | EV / Sales 2022 | 9,042,435,000 x |
| Net cash position 2022 | 1.8B 58.24B 2.47B | Net cash position 2023 | 1.63B 52.65B 2.23B | EV / Sales 2023 | 11,499,236,453 x |
| P/E ratio 2022 |
-134
x | P/E ratio 2023 |
-65
x | Employees | 33 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 100% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.31% | ||
| 1 week | -1.54% | ||
| Current month | +2.24% | ||
| 1 month | +27.86% | ||
| 3 months | +10.19% | ||
| 6 months | +2.90% | ||
| Current year | +1.27% |
1 week
30.70
32.85
1 month
24.6033.25
Current year
22.2033.25
1 year
22.2049.15
3 years
22.2073.60
5 years
22.2073.60
10 years
22.2073.60
| Managers | Title | Age | Since |
|---|---|---|---|
Chih Hui Yang
CEO | Chief Executive Officer | 46 | - |
Chun Wei Chen
DFI | Director of Finance/CFO | - | - |
Heng Yu Liu
CTO | Chief Tech/Sci/R&D Officer | - | 21-11-14 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hung Jen Yang
BRD | Director/Board Member | 55 | 21-05-30 |
Ming Yu Huang
BRD | Director/Board Member | - | 22-01-18 |
Shih Chia Lin
BRD | Director/Board Member | - | 21-05-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-03 | 31.9 | -0.31% | 250,107 |
| 24-05-02 | 32 | +2.56% | 301,725 |
| 24-04-30 | 31.2 | -2.95% | 593,563 |
| 24-04-29 | 32.15 | -0.77% | 535,434 |
| 24-04-26 | 32.4 | +2.53% | 1,318,416 |
End-of-day quote Taipei Exchange, May 02, 2024
More quotes
Locus Cell Co Ltd is a Taiwan-based company mainly engaged in the biotechnology and pharmaceutical business. The Company is currently expected to provide cell therapy contract manufacturing organization (CDMO) production and development services using a pilot Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme (PIC/S) good manufacturing practices (GMP) facility, with related technologies for cell therapy products (expected to include tissue engineering related products, CAR-T, iPSCs, MSC and other cell therapy applications), process development and process scale-up, analytical method development and validation, clinical GMP manufacturing process for clinical trials, and stability testing.
| 1st Jan change | Capi. | |
|---|---|---|
| +1.27% | 198M | |
| +8.96% | 105B | |
| -1.43% | 104B | |
| +4.40% | 22.94B | |
| -12.15% | 22.34B | |
| -4.36% | 19.25B | |
| -39.98% | 17.08B | |
| -10.04% | 16.96B | |
| +6.79% | 14.16B | |
| +38.61% | 12.63B |
- Stock Market
- Equities
- 6891 Stock
